Richard Gaster, M.D., Ph.D., is a Managing Partner at venBio with experience as a physician, entrepreneur, and life science investor.
He has helped to launch, invest, and serve on the board of or as board observer of a number of venBio companies including Akero Therapeutics (IPO 2019), Harmony Biosciences (IPO 2020), Ventyx Biosciences (IPO 2021), Pharvaris (IPO 2021), Elevation Oncology (IPO 2021), Acelyrin (IPO 2023), 35Pharma, Aeovian Pharmaceuticals, Alumis, Arrakis Therapeutics, Attralus, Entact Bio, and NorthSea Therapeutics.
Prior to joining venBio, Dr. Gaster served as the head of translational medicine at Pliant Therapeutics. As a key member of the founding management team, Dr. Gaster was instrumental in the formation and launch of Pliant Therapeutics from Third Rock Ventures where he previously served as a Senior Associate.
1700 Owens Street, Suite 595
San Francisco, CA 94158
1200 Westlake Ave N, Suite 900
Seattle, WA 98109
© 2024 venBio. All Rights Reserved.